Active ingredients: pazopanib
What it is used for
VOTRIENT is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (RCC). VOTRIENT is indicated for the treatment of patients with advanced (unresectable and/or metastatic) Soft Tissue Sarcoma (STS) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. The Phase III trial population excluded patients with gastrointestinal stromal tumour (GIST) or adipocytic soft tissue sarcoma.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Store in Original Container
- Lifetime is 24 Months.
Always read the label. If symptoms persist see your healthcare professional.
Modified capsule-shaped, white, film-coated tablets, one side plain and the other side debossed with an identifying code of 'GS UHL'.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient pazopanib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)